Clinical trials: Ondansetron
Schizophrenia
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with…
- Trial name
- NCT02614586
- Testing
- TAK-058, Ondansetron
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions
The purpose of this study is to compare the single-dose oral bioavailability of Ondansetron 8 mg orally disintegrating tablets of Ohm Laboratories (A subsidiary of Ranbaxy Pharmaceuticals, USA) with Zofran ODT® 8 mg orally…
- Trial name
- NCT01523119
- Testing
- Ondansetron
- Where
- India
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Gastroenteritis
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
The purpose of this study is to give children with gastroenteritis with persistent vomiting flavored intravenous ondansetron orally.
- Trial name
- NCT02473887
- Testing
- Ondansetron with1:1 ORA - sweet.
- Volunteers
- 40 people
- Sponsor
- Hamad Medical Corporation
Healthy
Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions
Single-dose cross over comparative bioavailability of Ondansetron 24 mg oDT and Zofran 24 mg ODT
- Trial name
- NCT00659074
- Testing
- Ondansetron, Zofran
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Post-Operative Nausea And Vomiting Study In Female Patients
The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.
- Trial name
- NCT00274690
- Testing
- GW679769
- Where
- 44 sites in United States, Denmark and 9 more
- Volunteers
- 435 people
- Sponsor
- GlaxoSmithKline
Healthy Participants
Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water
This study conducted in healthy male and female adult participants compared the bioavailability and relative safety and tolerance of a single dose of ondansetron 8 mg Orally Dissolving Filmstrip (ODFS) administered under fasting…
- Trial name
- NCT01220167
- Testing
- Ondansetron 8 mg ODFS without water, Ondansetron 8 mg ODFS with water, Zofran ODT (ondansetron 8 mg) without water
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Aquestive Therapeutics
Overweight, Obesity
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered alone and in combination with an antiemetic medication, ondansetron, in participants living with overweight or obesity.
- Trial name
- NCT07310563
- Testing
- AMG 133, Ondansetron
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Amgen
Healthy
Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
The objective of this study was to investigate the bioequivalence of Mylan's ondansetron 24 mg tablets to GSK's Zofran® 24 mg tablets following a single, oral 24 mg (1 x 24 mg) dose administered under fasting conditions.
- Trial name
- NCT00649532
- Testing
- Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Chemotherapy-induced Nausea and Vomiting
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (> 24-120…
- Trial name
- NCT02106494
- Testing
- APF530, Ondansetron, Fosaprepitant
- Where
- 7 sites in United States
- Volunteers
- 942 people
- Sponsor
- Heron Therapeutics
Postoperative Nausea and Vomiting
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
This study will evaluate single IV doses of Vestipitant (GW597599) compared to 4 mg IV ondansetron for treating breakthrough postoperative nausea and vomiting (PONV) after failure of PONV prophylaxis with a regimen that includes…
- Trial name
- NCT01507194
- Testing
- Ondansetron, Vestipitant
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- Accenture
Healthy
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers
This is a randomized, open-label Phase 1 pharmacokinetic, tolerability, and safety study of ondansetron and Hylenex given subcutaneously compared to ondansetron given intravenously, intramuscularly, and orally in normal healthy…
- Trial name
- NCT01572012
- Testing
- Ondansetron, Ondansetron + Hylenex, Zofran ODT
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Postoperative Nausea and Vomiting
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
The primary objective of this study is to evaluate the efficacy of a single palonosetron IV dose compared to a single ondansetron IV dose in the prevention of postoperative nausea and vomiting through 24 hours after surgery in…
- Trial name
- NCT01395901
- Testing
- Palonosetron, Ondansetron
- Where
- 44 sites in United States, Argentina and 6 more
- Volunteers
- 670 people
- Sponsor
- Helsinn Healthcare SA
Major Depressive Disorder (MDD)
A Study in Patients With Major Depressive Disorder
This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
- Trial name
- NCT03642964
- Testing
- CTC-501
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Chase Therapeutics Corporation
Nausea and Vomiting, Chemotherapy-Induced
To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects
Ondansetron, also known as Zofran, is a marketed compound used for the prevention of nausea and vomiting. This study, called a thorough QT study, will characterize the effects of a single intravenous (IV) dose of ondansetron on…
- Trial name
- NCT01449188
- Testing
- ondansetron, moxifloxacin, saline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vomiting, Nausea
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration…
- Conditions
- Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
- Trial name
- NCT00366834
- Testing
- Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous
- Where
- 223 sites in United States, Argentina and 30 more
- Volunteers
- 1,840 people
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study is designed to test the safety and the extent of the GW679769 affect on dexamethasone and ondansetron levels in humans.
- Trial name
- NCT00437229
- Testing
- Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Nausea, Vomiting
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
To demonstrate the relative bioavailability study of Ondansetron HCl 24 mg tablets under fasting conditions.
- Trial name
- NCT00946387
- Testing
- Ondansetron HCl 24 mg Tablets (Sandoz, Inc.), Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sandoz
Chemotherapy-Induced Nausea and Vomiting
A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00971633
- Testing
- Comparator: Treatment A (Zofran, ondansetron), Comparator: Treatment B (Zofran, ondansetron), Comparator: Treatment C (Zofran, ondansetron)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC